To launch Level II Applet click here.

From DNAPrint.com:
DNAPrintTM genomics, Inc. is a genomics science company focused on the sale of unique proprietary genetic testing
Products and services. The Company's core patented and proprietary technologies for efficiently targeting single nucleotide polymorphisms ("SNPs") enable us to provide novel predictive genetic tests at a significant cost advantage over our competitors. DnaPrint.com

Wall Street News Alert: Stock Watch Alert on DNAG! July 14, 2005 Distribution Source : Market Wire Date: Thursday - July 14, 2005 WESTON, FL -- (Market Wire - Jul 14, 2005) -- Wall Street News Alert's "stocks to watch" this morning are: DNAPrint genomics (OTC BB: DNAG), Sun Microsystems (NASDAQ: SUNW), Majesco Entertainment Company (NASDAQ: COOL) and Time Warner Cable (NYSE: TWX). DNAPrint genomics, Inc. (OTC BB: DNAG) may be appearing on the radar screen of aggressive investors and day traders this morning! Yesterday after the stock markets closed, the company issued a press release announcing that it has created a new product pipeline for its pharmaceutical products by acquiring an 18% stake in Biofrontera AG of Leverkusen, Germany, for 1.5 million Euros. The news of the acquired stake should be welcomed by investors! "Our relationship with Biofrontera will result in a new pharmaceutical pipeline for DNAPrint genomics," stated Mr. Gabriel, the Company's President and Chief Executive Officer. "Biofrontera already is in Phase II clinical trials with its BF-Derm1 lead product, an anti-itch compound for chronic Urticaria, known as chronic itching and welts brought on by exposure to cold or other allergens that cause a severe skin immune response. It also has a Phase II clinical trial compound for pre-cancerous skin lesions or actinic keratosis known as 5-aminolevulonic acid. Additionally, Biofrontera has advanced a novel prophylactic migraine treatment to pre-clinical development, as well as a series of other compounds at the pre-clinical stage." DNAPrint genomics appears poised to take advantage of this new relationship! Hector J. Gomez, M.D., Ph.D., DNAPrint's Chairman and Chief Medical Officer, said the Biofrontera investment is in line with the Company's corporate strategy to leverage its expertise in DNA technology in the development of pharmaceuticals. "We already have one drug in our product pipeline and have begun pre-clinical work with Harvard Medical School's Beth Israel Deaconess Medical Center on PT-401, or Super EPO, a more potent compound for the anemia drug erythropoietin (EPO)," Dr. Gomez said. "The key goal of our pharmaceutical research is the development of test/drug combinations for helping to ensure efficacy with compatible patients." Investors should continue to monitor the progress of DNAPrint genomics for further developments! According to the press release, the company also is continuing to expand its line of forensic products for the law enforcement market and family ancestry products for individual consumers. For updated in-depth coverage and a company profile of DNAPrint genomics, visit http://www.backissuesofnewsalerts.us/DNAG0713.html Prior to yesterday's press release, the stock closed at Fourteen cents a share. In case you are not familiar with the company: DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. Stocks showing interesting activity yesterday at the close of the regular trading day were: Sun Microsystems, Inc. (NASDAQ: SUNW) up 0.5% on 21.9 million shares traded, Majesco Entertainment Company (NASDAQ: COOL) down 48.3% on 19 million shares traded and Time Warner Cable (NYSE: TWX) down 0.1% on 20.1 million shares traded. Commentary: "News from the White House economists is expected to note that there will be a significant drop in the nation's budget deficit by $76 billion from 427 to around 350 billion. This is the first drop in the deficit since the year 2000. An increase in revenues from businesses and individuals is causing the improvement in the numbers say the experts," stated Sonja Rudd in Wall Street News Alert's daily commentary continued at: http://www.WallStreetNewsAlert.com. Let Wall Street News Alert help advertise for your company using our effective awareness campaigns. If you're interested in telling your story, we can help. Contact us at info@wallstreetnewsalert.com WSNA's email alert service is free to those investors who sign up on the WSNA home page. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to Special Situation companies that have the potential of showing increased activity. The Wall Street News Alert home page has experienced over 50 million hits. To subscribe to this free service, visit the Wall Street News Alert home page at http://www.wallstreetnewsalert.com and select the "join now" button. *** Wall Street News Alert is not affiliated with faxes bearing names such as: Wall Street Stock Alert, Wall Street Investor Alert, Wall Street News Alert or any other fax using various combinations of the generic words Wall Street! If you receive any such fax, please do not contact us at www.wallstreetnewsalert.com. You may wish to inquire about the fax with the CEO of the company that the fax is written about. *** Wall Street News Alert is a division of Wall Street Capital Funding LLC (WSCF). WSCF is not a registered broker/dealer and may not sell, offer to sell or offer to buy any security. WSCF profiles are not a solicitation or recommendation to buy, sell or hold securities. An offer to buy or sell can be made only with accompanying disclosure documents from the company offering or selling securities and only in the states and provinces for which they are approved. The material in this release is intended to be strictly informational. The companies that are discussed in this release have not approved the statements made in this release nor approved the timing of this release. All statements and expressions are the sole opinion of WSCF and are subject to change without notice. Information in this release is derived from a variety of sources including that company's publicly disseminated information, third parties and WSCF research. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. WSCF disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. The release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. WSCF is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment if they make a purchase in WSCF profiled stocks. This profile is not without bias, and is a paid release. WSCF has been compensated for dissemination of company information on behalf of one or more of the companies mentioned in this release. WSCF has been compensated Fourteen Thousand Dollars for coverage of DNAPrint genomics, Inc. (OTC BB: DNAG), by the company, for services provided including dissemination of company information in this release. WSCF holds no shares of the stock. WSCF may receive shares for extension of its services. Any shares will be disclosed at such time that WSCF is aware of a clients desire to extend the original services. WSCF may have received shares of a company profiled in this release prior to the dissemination of the information in this release. WSCF may immediately sell some or any shares in a profiled company held by WSCF and may have previously sold shares in a profiled company held by WSCF. WSCF's services for a company may cause the company's stock price to increase, in which event WSCF would make a profit when it sells its stock in a company. In addition, WSCF's selling of a company's stock may have a negative effect on the market price of the stock.